Gallbladder Cancer - Pipeline Review, H1 2016


#739372

64pages

Global Markets Direct

$ 2000

In Stock

Gallbladder Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Gallbladder Cancer - Pipeline Review, H1 2016, provides an overview of the Gallbladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gallbladder Cancer
- The report reviews pipeline therapeutics for Gallbladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gallbladder Cancer therapeutics and enlists all their major and minor projects
- The report assesses Gallbladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gallbladder Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gallbladder Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gallbladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gallbladder Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Gallbladder Cancer - Overview 8
Pipeline Products for Gallbladder Cancer - Comparative Analysis 9
Gallbladder Cancer - Therapeutics under Development by Companies 10
Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 11
Gallbladder Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Gallbladder Cancer - Products under Development by Companies 13
Gallbladder Cancer - Products under Investigation by Universities/Institutes 14
Gallbladder Cancer - Companies Involved in Therapeutics Development 15
4SC AG 15
Array BioPharma Inc. 16
Novartis AG 17
Spectrum Pharmaceuticals, Inc. 18
VasGene Therapeutics, Inc. 19
Gallbladder Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
binimetinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DKN-01 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
resminostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SPI-1620 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
trametinib dimethyl sulfoxide - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vas-01 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Gallbladder Cancer - Recent Pipeline Updates 50
Gallbladder Cancer - Dormant Projects 61
Gallbladder Cancer - Discontinued Products 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development for Gallbladder Cancer, H1 2016 8
Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Gallbladder Cancer - Pipeline by 4SC AG, H1 2016 15
Gallbladder Cancer - Pipeline by Array BioPharma Inc., H1 2016 16
Gallbladder Cancer - Pipeline by Novartis AG, H1 2016 17
Gallbladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 18
Gallbladder Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Gallbladder Cancer Therapeutics - Recent Pipeline Updates, H1 2016 50
Gallbladder Cancer - Dormant Projects, H1 2016 61
Gallbladder Cancer - Discontinued Products, H1 2016 62

List of Figures
Number of Products under Development for Gallbladder Cancer, H1 2016 8
Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

NA

NA